Literature DB >> 10146966

Test of an instrument to measure function-related quality of life in patients with ulcerative colitis.

A Zbrozek1, R Hoop, M Robinson, M McPherson.   

Abstract

An instrument for measuring function-related quality of life (QOL) in patients with ulcerative colitis was tested for validity, reliability, and responsiveness, using concepts and statistical methods easily understandable for pharmaceutical researchers. For this 8-week study, 374 patients were randomised and received placebo or oral mesalazine (mesalamine) at 1g, 2g, or 4g daily. A 10cm visual analogue scale and patient diaries were used to measure the 12 QOL parameters at baseline and study termination. Physician's Global Assessment was measured at end-point and used to assess change in the disease state of each patient. Analysis of covariance was used to test the construct validity, reliability and responsiveness of the instrument. Construct validity (p less than or equal to 0.0001), reliability (p greater than 0.05), and responsiveness (p less than or equal to 0.0001) were established for all 12 parameters of the instrument. We conclude that the instrument demonstrated precision in measuring function-related QOL in patients with active ulcerative colitis. Furthermore, content validity was maximised by combining disease-specific and general questions in the instrument.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 10146966     DOI: 10.2165/00019053-199304010-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  17 in total

1.  Quality of life in patients with inflammatory bowel disease.

Authors:  A Mitchell; G Guyatt; J Singer; E J Irvine; R Goodacre; C Tompkins; N Williams; F Wagner
Journal:  J Clin Gastroenterol       Date:  1988-06       Impact factor: 3.062

2.  Measuring change over time: assessing the usefulness of evaluative instruments.

Authors:  G Guyatt; S Walter; G Norman
Journal:  J Chronic Dis       Date:  1987

3.  Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas.

Authors:  K W Somerville; M J Langman; S P Kane; A J MacGilchrist; G Watkinson; P Salmon
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-28

4.  The AIMS approach to health status measurement: conceptual background and measurement properties.

Authors:  R F Meenan
Journal:  J Rheumatol       Date:  1982 Sep-Oct       Impact factor: 4.666

5.  Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.

Authors:  W O Spitzer; A J Dobson; J Hall; E Chesterman; J Levi; R Shepherd; R N Battista; B R Catchlove
Journal:  J Chronic Dis       Date:  1981

6.  The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.

Authors:  J F Fries; P W Spitz; D Y Young
Journal:  J Rheumatol       Date:  1982 Sep-Oct       Impact factor: 4.666

7.  Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease.

Authors:  R M Kaplan; C J Atkins; R Timms
Journal:  J Chronic Dis       Date:  1984

8.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

9.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study.

Authors:  A L Stewart; S Greenfield; R D Hays; K Wells; W H Rogers; S D Berry; E A McGlynn; J E Ware
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

10.  The development of a method for assessing the quality of life of cancer patients.

Authors:  P J Selby; J A Chapman; J Etazadi-Amoli; D Dalley; N F Boyd
Journal:  Br J Cancer       Date:  1984-07       Impact factor: 7.640

View more
  4 in total

Review 1.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 2.  Quality of life measurement in gastrointestinal and liver disorders.

Authors:  M R Borgaonkar; E J Irvine
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

3.  Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia.

Authors:  T F Cutts; T L Abell; J G Karas; J Kuns
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

4.  Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?

Authors:  Emma M van Andel; Brechtje D M Koopmann; Femke Crouwel; Casper G Noomen; Nanne K H de Boer; Dirk P van Asseldonk; Lidwine B Mokkink
Journal:  J Crohns Colitis       Date:  2020-09-16       Impact factor: 9.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.